# US 2020/0390913 A1 · Radiolabeled progastrin in cancer diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390913 A1
- Document ID: US20200390913A1
- Status: Published application
- Kind: A1
- Application number: 16/770,180
- Filed: 2018-12-10
- Published: 2020-12-17
- Earliest claimed: 2017-12-08
- Assignees: ECS-Biotracker SÀRL
- Applicants: ECS-Biotracker SÀRL
- Inventors: Jean-François Floch
- Web page: https://patentgrep.com/patent/US20200390913A1

## CPC

- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- C07K 1/13: Labelling of peptides
- C07K 14/595: Gastrins; Cholecystokinins [CCK]
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a radiotracer comprising a progastrin moiety, a chelating moiety and a radioisotope. Uses of said biomarker for imaging and detecting cancers in a subject are also provided. In one embodiment, the radiotracer is 68Ga-NODAGA-Progastrin.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, comprising:
a progastrin moiety, and
a chelating moiety.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the progastrin moiety is the peptide of sequence SEQ ID NO:1.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the chelating moiety is a bifunctional chelator.

### Claim 4 (depends on 3)

The compound of claim 3, wherein the bifunctional chelator is selected from the group consisting of NODAGA, NOTA, DOTA, DOTA-NHS, p-SCN-Bn-NOTA, p-SCN-Bn-PCTA, p-SCN-Bn-oxo-DO3A, desferrioxamine-p-SCN, DTPA, and TETA.

### Claim 5 (depends on 3)

The compound of claim 3, wherein the bifunctional chelator is NODAGA, NOTA, or DOTA.

### Claim 6 (depends on 3)

The compound of claim 3, wherein the bifunctional chelator is NODAGA.

### Claim 7 (depends on 1)

The compound of claim 1, further comprising a radioisotope selected from the group consisting of 68Ga, 64Cu, 89Zr, 186/188Re, 90Y, 177Lu, 153Sm, 213Bi, 225Ac, 111In, 99mTc, 123I, and 223Ra.

### Claim 8 (depends on 7)

The compound of claim 7 any, wherein the radioisotope is 68Ga or 64Cu.

### Claim 9 (depends on 7)

The compound of claim 7, wherein the radioisotope is 68Ga.

### Claim 10 (depends on 1)

A method of preparing the compound of claim 1, comprising the steps of:
a) conjugating an amine-reactive chelating moiety to the progastrin moiety; and
b) recovering the conjugate of progastrin and chelator.

### Claim 11 (depends on 10)

The method of claim 10, wherein the amine-reactive chelating moiety is DOTA-NHS, NOTA-NHS, or NODAGA-NHS ester.

### Claim 12 (depends on 10)

The method of claim 10, wherein the amine-reactive chelating moiety is NODAGA-NHS ester.

### Claim 13 (depends on 1)

The method of claim 1, further comprising a step of:
c) incubating the conjugate of progastrin and chelator with the complementary radioisotope;
thus generating the compound of the invention.

### Claim 14

A method of imaging one or more cancer cells, organs, or tissues in a subject in recognized need thereof, comprising:
a) administering a compound, or a pharmaceutically acceptable salt thereof, to said subject; and
b) detecting the compound by in vivo PET or SPECT imaging,
wherein the compound comprises:
a progastrin moiety, and
a chelating moiety.

### Claim 15

A method of determining the localisation of a cancer in a subject in need thereof, comprising:
a) administering a compound, or a pharmaceutically acceptable salt thereof, to said subject; and
b) detecting the compound by in vivo PET or SPECT imaging:
wherein the compound comprises:
a progastrin moiety, and
a chelating moiety.

### Claim 16 (depends on 15)

The method of claim 15, further comprising a prior step of determining the level of progastrin in sample of said subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the level of progastrin is determined with anti-progastrin antibodies.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A kit comprising a compound of claim 1.
